Skip to content

Study · Observational study · 2024

3 results

Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.

Horii T, Masudo C, Takayanagi Y, Oikawa Y, Shimada A, Mihara K

Journal of diabetes investigation7 Sept 2024Cited by 19 (Europe PMC)

PMID39243175 (opens in a new tab)PMCIDPMC11527826 (opens in a new tab)DOI10.1111/jdi.14265 (opens in a new tab)PepBankPUB-39243175
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyOther

    In adults with type 2 diabetes in a claims database, once-weekly subcutaneous semaglutide had higher odds of non-adherence than oral semaglutide at 12 months (odds ratio 1.39).

    In plain wordsIn adults with type 2 diabetes, people on the weekly semaglutide injection were less likely to take it as prescribed than people on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseNon-adherence (proportion of days covered below 0.8)
    Study

    n: not reported in source

    Comparator
    Oral semaglutide (O-SEMA)
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · oral or subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    SEMA-SC had a significantly higher odds ratio (OR) for non-adherence than O-SEMA (OR: 1.39).
    3 context sentences
    Summary · context
    Non-adherence was defined as <0.8 of the proportion of days covered.
    Summary · context
    This retrospective observational study compared the 12 month adherence and treatment discontinuation of O-SEMA and once-weekly SEMA-SC in patients with type 2 diabetes using a real-world claims database.
    Summary · context
    SEMA-SC initiators were 1:1 propensity score-matched to O-SEMA initiators.
  2. 02HumanObservational studyOther

    In adults with type 2 diabetes in a claims database, once-weekly subcutaneous semaglutide had a higher hazard of treatment discontinuation than oral semaglutide (hazard ratio 1.45).

    In plain wordsIn adults with type 2 diabetes, people on the weekly semaglutide injection were more likely to stop treatment than people on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment discontinuation
    Study

    n: not reported in source

    Comparator
    Oral semaglutide (O-SEMA)
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · oral or subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The hazard ratio for treatment discontinuation, using O-SEMA as the reference, was 1.45 for SEMA-SC
    2 context sentences
    Summary · context
    This retrospective observational study compared the 12 month adherence and treatment discontinuation of O-SEMA and once-weekly SEMA-SC in patients with type 2 diabetes using a real-world claims database.
    Summary · context
    SEMA-SC initiators were 1:1 propensity score-matched to O-SEMA initiators.
  3. 03HumanObservational studyOther

    In adults with type 2 diabetes in a claims database, the discontinuation rate of oral semaglutide was higher than that of subcutaneous semaglutide during the early stage.

    In plain wordsIn adults with type 2 diabetes, more people stopped oral semaglutide than the weekly injection in the early months.

    Peptide
    Semaglutide
    Outcome
    IncreaseEarly-stage discontinuation rate
    Study

    n: not reported in source

    Comparator
    Once-weekly subcutaneous semaglutide (SEMA-SC)
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · oral or subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    although the discontinuation rate of O-SEMA was higher during the early stage.
    2 context sentences
    Summary · context
    This retrospective observational study compared the 12 month adherence and treatment discontinuation of O-SEMA and once-weekly SEMA-SC in patients with type 2 diabetes using a real-world claims database.
    Summary · context
    SEMA-SC initiators were 1:1 propensity score-matched to O-SEMA initiators.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.